CTPS1: The Potential Drug Target and Biomarker (G1503)

Target Name: CTPS1

NCBI ID: G1503

CTPS1

CTPS1: The Potential Drug Target and Biomarker

CTPS1 (Cysteinyl-Tyrine-Protein-Sulfurase 1) is a protein that is expressed in various tissues throughout the body, including the liver, pancreas, and heart. It is a member of the superfamily of cysteinyl-proteinases (CSPs), which are a group of enzymes that belong to the family of serine proteases. CSPs are involved in the regulation of a wide range of cellular processes, including cell signaling, inflammation, and stress responses. In addition to its role in cellular signaling, CTPS1 has also been shown to play a potential role as a drug target and biomarker.

The discovery of CTPS1 as a potential drug target comes from a study by the research group of Dr. Xujiong Ye at the University of California, San Diego. In this study, the researchers found that inhibiting the activity of CTPS1 using small molecules inhibited the production of reactive oxygen species (ROS) in cell culture, which are highly reactive molecules that can cause damage to cells if they are not properly regulated. This suggests that CTPS1 may be a source of ROS, which could make it an attractive target for drugs that are designed to inhibit oxidative stress and prevent cellular damage.

Another study by Dr. Zongqing Zhao and his colleagues at the University of California, San Diego also identified CTPS1 as a potential biomarker for the diagnosis of pancreatic cancer. The researchers used a combination of genetic and biochemical approaches to identify mutations in the CTPS1 gene that were associated with the development of pancreatic cancer. They found that mutations in the CTPS1 gene were frequently observed in pancreatic cancer samples, and that these mutations were associated with poor prognosis. This suggests that CTPS1 may be a useful biomarker for the diagnosis and prognosis of pancreatic cancer.

In addition to its potential use as a drug target and biomarker, CTPS1 is also of interest as a potential therapeutic target for a wide range of diseases. The cysteinyl-proteinases (CSPs) are involved in the regulation of a wide range of cellular processes, including cell signaling, inflammation, and stress responses. As such, CTPS1 may be a useful target for drugs that are designed to modulate the activity of CSPs. This could be particularly useful for the treatment of diseases that are characterized by the production of reactive oxygen species (ROS), such as oxidative stress-induced diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, CTPS1 is a protein that has been identified as a potential drug target and biomarker. The inhibition of its activity using small molecules has been shown to result in the inhibition of ROS production, which suggests that it may be an attractive target for drugs that are designed to inhibit oxidative stress and prevent cellular damage. Further research is needed to fully understand the role of CTPS1 as a potential therapeutic target for a wide range of diseases.

Protein Name: CTP Synthase 1

Functions: This enzyme is involved in the de novo synthesis of CTP, a precursor of DNA, RNA and phospholipids. Catalyzes the ATP-dependent amination of UTP to CTP with either L-glutamine or ammonia as a source of nitrogen. This enzyme and its product, CTP, play a crucial role in the proliferation of activated lymphocytes and therefore in immunity

The "CTPS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTPS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets